Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05629962 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 | PHASE3 | COMPLETED | 2,285 | — | — | Nov 25, 2022 | May 30, 2024 | Jun 13, 2025 | 263 | United States, Argentina +17 |
| Arm | Type | Description |
|---|---|---|
| Bemnifosbuvir (BEM) | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bemnifosbuvir (BEM) | DRUG | BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days |
| Placebo | DRUG | Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days |
Inclusion Criteria: * Positive SARS-CoV-2 test conducted ≤ 5 days prior to randomization * Mild or moderate COVID-19 with symptom onset ≤ 5 days before randomization and at least one COVID-19 related symptom present at time of screening * Subject must be high risk, defined below: 1. Age ≥70 year...